文献速递自身免疫性与大疱性皮肤病

EQ-5D在寻常型天疱疮与落叶型天疱疮患者中的效度

Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus.
PubMed 文献 · Br J Dermatol · 2018-09-19

2014至2017年多中心横断面研究纳入109例连续性天疱疮患者,采用EQ-5D-5L、DLQI、ABSIS及过去3个月平均疼痛强度VAS评估健康相关生活质量。EQ-5D各维度中疼痛/不适报告问题最多(50%),寻常型与落叶型天疱疮患者EQ-5D指数得分无显著差异(0.81 vs 0.86,P=0.14)。EQ-5D指数得分随天疱疮严重程度增加而降低(P=0.001),合并症数量与EQ-5D指数得分受损更重相关(P<0.001)。

要点

  • 天疱疮患者EQ-5D问题最多的维度为疼痛/不适(50%)、活动能力(43%)和焦虑/抑郁(43%)。
  • 寻常型与落叶型天疱疮患者EQ-5D指数得分无显著差异(0.81 vs 0.86,P=0.14)。
  • EQ-5D指数得分与DLQI(rs=-0.62,P<0.001)和平均疼痛强度VAS(rs=-0.59,P<0.001)的相关性强于ABSIS(rs=-0.40,P<0.001)。

核心结论

  • EQ-5D是天疱疮患者健康相关生活质量的有效测量工具,可用于临床实践和经济评价中评估新型有效治疗带来的健康获益。

研究设计与样本

  • 2014至2017年开展的多中心横断面研究,共纳入109例连续性天疱疮患者(平均年龄57岁;64%为女性)。

主要发现

  • EQ-5D各维度中报告问题最多的为疼痛/不适(50%)、活动能力(43%)和焦虑/抑郁(43%)。
  • 寻常型天疱疮与落叶型天疱疮患者平均EQ-5D指数得分无显著差异(0.81 vs 0.86,P=0.14)。
  • 局限型、中度、显著和极重度天疱疮患者平均EQ-5D指数得分分别为0.88、0.82、0.72和0.67(P=0.001)。
  • 合并症数量与EQ-5D指数得分受损更重相关(P<0.001)。
  • DLQI(rs=-0.62,P<0.001)和过去3个月平均疼痛强度VAS(rs=-0.59,P<0.001)与EQ-5D指数得分的相关性均强于ABSIS(rs=-0.40,P<0.001)。

关键数值与推荐

  • EQ-5D-5L、DLQI、ABSIS及过去3个月平均疼痛强度VAS为结局测量工具。
  • EQ-5D指数得分在局限型、中度、显著和极重度天疱疮患者中分别为0.88、0.82、0.72和0.67(P=0.001)。
  • 合并症数量与EQ-5D指数得分受损更重相关(P<0.001)。

临床怎么用

  • EQ-5D可用于临床实践和经济评价中评估天疱疮患者健康相关生活质量及新型有效治疗带来的健康获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No studies to date have employed the EuroQoL EQ-5D questionnaire to assess health-related quality of life (HRQoL) in patients with pemphigus. OBJECTIVES: To evaluate the HRQoL of patients with pemphigus by the EQ-5D and to analyse the convergent and known-groups validity of the EQ-5D in this patient population. METHODS: Between 2014 and 2017, a multicentre cross-sectional study was carried out. Outcome measures included the five-level EQ-5D (EQ-5D-5L), Dermatology Life Quality Index (DLQI), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and an average pain intensity visual analogue scale (VAS) for the past 3 months. RESULTS: In total, 109 consecutive patients with pemphigus participated in the study (mean age 57 years; 64% women). Among the EQ-5D dimensions, the most problems were reported regarding pain/discomfort (50%), mobility (43%) and anxiety/depression (43%). No significant difference was found in mean EQ-5D index scores between patients with pemphigus vulgaris and those with pemphigus foliaceus (0·81 vs. 0·86, P = 0·14). The mean EQ-5D index scores of patients with limited, moderate, significant and extreme pemphigus were 0·88, 0·82, 0·72 and 0·67, respectively (P = 0·001). The number of comorbidities was associated with greater impairment in EQ-5D index scores (P < 0·001). DLQI (rs = -0·62, P < 0·001) and the average pain intensity VAS (rs = -0·59, P < 0·001) more strongly correlated with the EQ-5D index scores than did ABSIS (rs = -0·40, P < 0·001). CONCLUSIONS: This is the first study employing the EQ-5D questionnaire in pemphigus. The EQ-5D is a valid measure of HRQoL in patients with pemphigus that can be useful both in clinical practice and in economic evaluations to assess the health gains associated with new effective treatments.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Tamási B, Brodszky V, Péntek M, et al. Validity of the EQ-5D in patients with pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol. 2018. PMID: 29897626. doi:10.1111/bjd.16883

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。